Loading...
Market
Will Intellia finalize NTLA-2002 dosing for pivotal trials by September 30, 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcement from Intellia Therapeutics or clinical trial registry updates
Story
Intellia's NTLA-2002 Phase 1 CRISPR-Based Treatment Shows Promising Results in HAE
Jun 3, 2024, 12:49 AM
Intellia Therapeutics has announced positive long-term data from its ongoing Phase 1 study of NTLA-2002, a CRISPR-based treatment for hereditary angioedema (HAE). The data, presented at the EAACI 2024 Congress, showed a dramatic reduction in patients' swelling attacks. Despite the promising results, there are discussions about the appropriate dosing for pivotal trials. Some analysts, including RNAiAnalyst, suggest that a 75mg dose would be clearly superior due to its efficacy with a -95% reduction in PKK, though Intellia is currently only considering 25mg and 50mg doses due to safety concerns.
View original story
Similar markets
Phase 3 trial initiation • 33%
Phase 3 trial completion • 33%
FDA submission • 34%
FDA confirms significant side effects • 50%
FDA denies significant side effects • 50%
